SCHEMBL2908324

SCHEMBL2908324

CC(C)(C)c1cc(CCc2ccc(NS(C)(=O)=O)cc2)cc(N2C(=O)CCNC2=O)c1

nearest known ligand 0.39

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 1/20 0.39
CYP3A4 P08684 1/20 0.38
EPHX2 P34913 1/20 0.38
NR1H4 Q96RI1 1/20 0.38
GRIN1 Q05586 1/20 0.36
GRIN2B Q13224 1/20 0.36
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36
LMNA P02545 1/20 0.36
HPGD P15428 1/20 0.36
HTT P42858 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2912906 0.83 CYP3A4 (0.39) TRPV1CYP3A4EPHX2NR1H4
SCHEMBL2910649 0.82 TDP2 (0.33) TRPV1EPHX2NR1H4ALDH1A1
SCHEMBL2113416 0.81 CYP3A4 (0.56) CYP3A4GRIN1GRIN2BKDM4EALDH1A1
SCHEMBL2909890 0.80 CA1 (0.42) TRPV1EPHX2NR1H4KDM4EALDH1A1
SCHEMBL2912524 0.80 RAB9A (0.44) TRPV1EPHX2NR1H4KDM4EALDH1A1
SCHEMBL1530884 0.78 DDB1 (0.39) TRPV1CYP3A4EPHX2NR1H4GRIN1
SCHEMBL2908431 0.76 KAT2B (0.32) ALDH1A1
SCHEMBL2915590 0.75 GAA (0.36) EPHX2NR1H4HPGD
SCHEMBL2916119 0.73 ALOX12 (0.37) TRPV1CYP3A4EPHX2NR1H4
SCHEMBL2914859 0.73 CYP3A4 (0.40) CYP3A4EPHX2NR1H4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2725015-A1 Uracil or thymine derivative for treating hepatitis c AbbVie Bahamas Ltd. (BS) 2014-04-30 EP claimed
EP-2222646-A1 URACIL OR THYMINE DERIVATIVE FOR TREATING HEPATITIS C Abbott Laboratories (US) 2010-09-01 EP disclosed
WO-2009039127-A1 URACIL OR THYMINE DERIVATIVE FOR TREATING HEPATITIS C ABBOTT LABORATORIES (US) 2009-03-26 WO disclosed